Theravance Biopharma, Inc. Derivative Asset
Theravance Biopharma, Inc. (TBPH) had Derivative Asset of $2.33 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:DerivativeAssets · last filed 2026-08-11
- 2026-06-30: Derivative Asset $2.33M.
- 2026-03-31: Derivative Asset $2.34M.
- 2025-12-31: Derivative Asset $2.38M.
- 2025-09-30: Derivative Asset $2.39M.
| Period end | Derivative Asset |
|---|---|
| 2026-06-30 | $2.33M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.34M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.38M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $2.39M 10-Q · filed 2025-11-12 |
| 2024-12-31 | $2.29M 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |